With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

The childhood obesity epidemic in GCC countries has triggered a debate on the potential use of weight-loss medications such ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Medications like Ozempic and Wegovy have made waves for weight loss, but they're not for everyone. If you've been put off by ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide ... 25% body weight loss compared to ...

The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss. The study ... doses of either Zepbound or Wegovy for more than a year. The results affirm what separate ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...

While Wegovy has been a leading treatment in the weight loss sector, Zepbound’s results in the trial suggest it could emerge as a strong contender. Lilly plans to present more detailed findings ...